Brian Park, PharmD

Drug Information Specialist https://www.dermatologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Aesthetic Medicine

FDA Approves Qwo to Treat Moderate to Severe Cellulite

Brian Park, PharmD

July 13, 2020

Results from both studies showed treatment with Qwo was associated with greater reductions in cellulite severity compared with placebo as measured by CR-PCSS and PR-PCSS scales at day 71.

Practice Management

Pfizer, BioNTech’s COVID-19 Vaccine Candidate Looks Promising in Early Human Trial

Brian Park, PharmD

July 7, 2020

Pfizer and BioNTech SE announced positive preliminary results from the phase 1/2 study evaluating the safety, tolerability, and immunogenicity of escalating doses of the vaccine candidate BNT162b1 against COVID-19.

Infections

Sivextro Approval Expanded to Include Pediatric Patients

Brian Park, PharmD

July 1, 2020

The FDA has expanded the approval of Sivextro.

Practice Management

Phase 1 Study of Adjuvanted COVID-19 Vaccine Candidate Begins

Brian Park, PharmD

July 1, 2020

A phase 1 study evaluating the safety, reactogenicity and immunogenicity of SCB-2019, a vaccine candidate for coronavirus disease 2019 (COVID-19), has been initiated by Clover Biopharmaceuticals.

Skin Cancer

Keytruda Approved for Cutaneous Squamous Cell Carcinoma

Brian Park, PharmD

June 30, 2020

The FDA has approved Keytruda (pembrolizumab; Merck) for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.

Acne

Arazlo Lotion Now Available for Acne Vulgaris

Brian Park, PharmD

June 29, 2020

Arazlo™ (tazarotene; Bausch Health Companies) Lotion 0.045% is now available for the topical treatment of acne vulgaris in patients aged ≥9 years.

Dermatitis

Improvements in Skin Clearance, Itch Observed With Upadacitinib in Atopic Dermatitis Study

Brian Park, PharmD

June 25, 2020

Topline results from a phase 3 study evaluating upadacitinib monotherapy in patients aged ≥12 years with moderate to severe atopic dermatitis (AD) showed the treatment was associated with significant improvement in skin clearance.

Acne

Resistance Data Added to Labeling for Acne Drug Seysara

Brian Park, PharmD

June 23, 2020

The FDA has approved updated labeling for Seysara® (sarecycline; Almirall LLC) to include information stating that Propionibacterium acnes (recently renamed Cutibacterium acnes) strains displayed a low propensity for the development of resistance to sarecycline.

AAD 2020

Superior Skin Clearance Observed With Risankizumab in Head-to-Head Psoriasis Study

Brian Park, PharmD

June 19, 2020

New data from a head-to-head study comparing risankizumab-rzaa to secukinumab in patients with moderate to severe plaque psoriasis were recently presented online at the American Academy of Dermatology virtual annual meeting.

Dermatitis

Positive Results With Abrocitinib in Adolescent Atopic Dermatitis Trial

Brian Park, PharmD

June 17, 2020

Positive topline results were announced from the phase 3 JADE TEEN study evaluating abrocitinib (Pfizer), a Janus Kinase (JAK) inhibitor, in patients aged 12 to <18 years with moderate to severe atopic dermatitis who were also on background topical therapy.

Next post in Dermatitis